These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 2839115)
21. [Role of the cut-off value of serum neuron-specific enolase in differentiating small cell lung cancer from non-small cell lung cancer]. Wei T; Luo RC; Zuo Q; Zhang JY; Miao JX; Lu HF Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):858-9. PubMed ID: 16793621 [TBL] [Abstract][Full Text] [Related]
22. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Ebert W; Muley T; Drings P Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537 [TBL] [Abstract][Full Text] [Related]
23. [Serum NSE (neuron-specific enolase) levels in small cell lung cancer, with special reference to the measurement of serial serum NSE levels]. Kawachi S; Shimabukuro Z; Aoyama A; Yano T; Hasegawa K; Tsuboi E; Niitani H Gan To Kagaku Ryoho; 1987 Aug; 14(8):2469-74. PubMed ID: 3039919 [TBL] [Abstract][Full Text] [Related]
24. Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis. Boher JM; Pujol JL; Grenier J; Daurès JP Br J Cancer; 1999 Mar; 79(9-10):1419-27. PubMed ID: 10188885 [TBL] [Abstract][Full Text] [Related]
25. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318 [TBL] [Abstract][Full Text] [Related]
26. Cut-off levels of NSE to differentiate SCLC from NSCLC. Satoh H; Ishikawa H; Kurishima K; Yamashita YT; Ohtsuka M; Sekizawa K Oncol Rep; 2002; 9(3):581-3. PubMed ID: 11956631 [TBL] [Abstract][Full Text] [Related]
27. Neuron-specific enolase (NSE) serum level in non small cell lung cancer--can it be an indicator of tumour chemosensitivity? Zych J; Sakowicz A; Radzikowska E; Załeska J; Rowińska-Zakrzewska E Rocz Akad Med Bialymst; 1997; 42 Suppl 1():173-8. PubMed ID: 9337535 [TBL] [Abstract][Full Text] [Related]
28. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381 [TBL] [Abstract][Full Text] [Related]
29. Neuron-specific enolase in small-cell carcinoma of the lung: the value of combined immunocytochemistry and serum determination. Esscher T; Bergh J; Steinholtz L; Nöu E; Nilsson K; Påhlman S Anticancer Res; 1989; 9(6):1717-20. PubMed ID: 2560624 [TBL] [Abstract][Full Text] [Related]
30. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer? Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424 [TBL] [Abstract][Full Text] [Related]
31. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer]. Pan QR; Zhang X; Xu ZF; Zheng S Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076 [TBL] [Abstract][Full Text] [Related]
32. [Treatment monitoring of patients with small cell lung cancer by determining levels of serum neuron specific enolase]. Jassem E Pneumonol Alergol Pol; 1993; 61(1-2):56-60. PubMed ID: 8388760 [TBL] [Abstract][Full Text] [Related]
33. [Clinical evaluation of serum NSE (neuron specific enolase) levels in cases of small cell lung cancer]. Moriya H; Hisa S; Satoh T; Suzuki S; Kimura K; Higuchi Y; Hoshi K Rinsho Hoshasen; 1988 Jan; 33(1):31-4. PubMed ID: 2835529 [No Abstract] [Full Text] [Related]
34. [Serial measurements of serum carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) during chemotherapy of patients with inoperable lung cancer]. Fukuoka M; Takada M; Kamei T; Negoro S; Kusunoki Y; Matsui K; Ryu S; Sakai N; Takifuji N; Masuda N Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):871-80. PubMed ID: 3032108 [TBL] [Abstract][Full Text] [Related]
35. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Okusaka T; Eguchi K; Kasai T; Kurata T; Yamamoto N; Ohe Y; Tamura T; Shinkai T; Saijo N Clin Cancer Res; 1997 Jan; 3(1):123-7. PubMed ID: 9815547 [TBL] [Abstract][Full Text] [Related]
36. [The changes in serum neuron-specific enolase in patients with small cell lung cancer]. Taitou H; Sakurai M; Tamura T; Sasaki Y; Eguchi K; Shinkai T; Ookura H; Saijo N Gan To Kagaku Ryoho; 1987 Nov; 14(11):3046-9. PubMed ID: 2823722 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of Cyfra 21-1 as a marker for lung cancer. Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188 [TBL] [Abstract][Full Text] [Related]
38. Combined measurements of neuron specific enolase and bombesin/gastrin releasing peptide in lung cancer. Scagliotti GV; Piani M; Gatti E; Gozzelino F; Albera C; Pozzi E Eur Respir J; 1989 Sep; 2(8):746-50. PubMed ID: 2553476 [TBL] [Abstract][Full Text] [Related]
40. [The prognostic value of serum neuron specific enolase detection in small cell lung cancer]. Jin B; Zhao L; Zhou C Zhonghua Jie He He Hu Xi Za Zhi; 2001 Dec; 24(12):722-4. PubMed ID: 11930699 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]